A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

The study targets adults in China with overweight or obesity accompanied metabolic dysfunction-associated fatty ... semaglutide 2.4 mg. The primary endpoints are the percentage change in liver ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

No treatments currently exist for the fatty liver disease, but the market could ... 3 because patients with more advanced disease showed benefits. Oclivia’s phase 2 trial was more conclusive ...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver ... improvements in liver fat levels and liver injury in the combination arms versus semaglutide alone.

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...

MCT oil (Medium-Chain Triglyceride oil) has gained popularity for its potential benefits in weight loss, metabolism, and brain health, and when its comes to its role in fatty liver disease ...

This discovery could lead to new drugs for treating fatty liver disease. Clinical trials are showing good therapeutic benefits. Researchers at Oklahoma University found that the hormone FGF21 can ...

A pioneering research study details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to ...